Prolific Machines’ Photomolecular Platform uses molecular optogenetics to dynamically regulate gene expression in mammalian cell lines using light. Our platform enables novel solutions for the production of next-generation biologics, including tunable control of target genes and genes that facilitate PTMs. Data will showcase gains in yields and manufacturability, paving the way for scalable, low-COGS production of complex biologics.

PUREfrex is a revolutionary, fully reconstituted cell-free protein expression system designed to redefine protein production. Its unparalleled flexibility suits a wide range of applications, including the production of difficult-to-express/therapeutic proteins and high-throughput screening. PUREfrex enables efficient in vitro display, facilitating the discovery of novel antibodies and cyclic peptides, and combined with AI/ML, PUREfrex accelerates the development of next-generation biologics.

Biopharmaceuticals are complex molecules with unique properties, known as critical quality attributes (CQAs), that are shaped by post-translational modifications in the cellular environment. Glycosylation, a key CQA, significantly influences the activity, efficacy, and half-life of biopharmaceuticals. During biopharmaceutical development, various process steps can affect the final glycan profile of a protein drug, providing opportunities to fine-tune the glycan species in the final product. Here we present a strategy that combines host cell selection and engineering, bioprocess optimisation combined with targeted analytical techniques to ultimately achieve desired glycan profiles in commercial manufacturing processes.

The development of biotherapeutic products is complex and the growing prevalence of next-generation and difficult-to-express formats places increasing demands on CHO expression systems to deliver high yield, scalable, and quality consistent bioproduction. Maximising the potential of an expression system requires precise coordination between various elements of upstream production, starting with the crucial first step of DNA vector design. In this presentation, we detail how Lonza has developed advanced GS expression vector technology that can power high titers, excellent product quality and long-term expression stability for a range of product types. We’ll cover how implementing a proven expression system early in development, alongside early de-risking strategies can help pave the way for successful biotherapeutic drug development, whatever the molecule type.

The successful development of biotherapeutic molecules begins with the generation of a robust cell line. Choosing the right Cell Line Development (CLD) path is essential and should be focused on both comprehensive analysis of protein-to-be-expressed attributes and specific programs needs assessment. To reach this goal, KBI Biopharma has leveraged the Selexis’ proprietary CHO-M™ and CHOKOL8™ (afucosylated) cell lines to design comprehensive and modular CLD workflows without compromising the successful inherited assets from our former random expression platform. We have developed a transposase-based expression platform that overcomes CLD challenges and deliver high-expressing cell lines up to 12 g/L with stability over 60 generations. In this “trust our experts” approach, we offer flexible and scalable solutions to ensure the best cell line development path for easy and difficult-to-express (DTE) molecules.

Solute carriers (SLCs) import and export a range of substrates, including nutrients, neurotransmitters, and pharmaceuticals. Despite being attractive therapeutic targets, this protein superfamily is relatively under-drugged. Therapeutic discovery is impeded by difficulties in the expression and purification of these membrane-embedded proteins. Here, we demonstrate methods to obtain high-purity, milligram quantities of human SLC transporter proteins suitable for structure determination, target engagement assays, and high-throughput screening.